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a b s t r a c t
Background: Osteoclasts differentiated from bone marrow macrophages (BMMs) induced by
TNF-a alone do not have resorbing activity. When BMMs are stimulated with receptor
activator of NF-kB ligand (RANKL) before TNF-a stimulation, pit-forming osteoclasts are
differentiated. However, the details of the effect of RANKL pretreatment on the pit-forming
osteoclast differentiation by TNF-a have not been established. The aim of this study is to
examine the condition of RANKL pretreatment for differentiation of pit-forming osteoclasts
induced by TNF-a.
Murine BMMs were stimulated with various concentrations of RANKL for 24 h in the
presence of M-CSF, then the medium was changed and TNF-a was added. Osteoclasts and
pits formation were examined. Osteoprotegerin (OPG), decoy receptor of RANKL, was added
to the culture to examine the necessity of co-existing RANKL with TNF-a on the formation of
pit-forming osteoclasts. To investigate the influence of RANKL of sufficient concentration as
pretreatment for pit-forming osteoclast formation by TNF-a, dose- and time-dependent
changes of osteoclast formation were checked.
Results: The pit formation by osteoclasts in response to TNF-a required 10 ng/mL RANKL
pretreatment. Stimulation with this concentration of RANKL led to the differentiation of
mature osteoclasts in the 72 h culture. The pit formation was not inhibited by the OPG.
Conclusion: These results suggested that the concentration of RANKL pretreatment, which
also alone can differentiate BMMs into osteoclasts, may be important in the differentiation
of pit-forming osteoclasts by TNF-a. In addition, the effects of TNF-a after RANKL treatment
might be independent of RANKL.
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Tumour necrosis factor-a (TNF-a) is reported to accelerate
bone resorption in inflammatory bone diseases such as
periodontitis and rheumatoid arthritis.1,2 Osteoclasts are
derived from monocyte-macrophage progenitor cells; they
play a central role in bone resorption.3,4 The monocyte-
macrophage progenitor cells differentiate into osteoclast
precursors when they are stimulated with macrophage-
colony stimulating factor (M-CSF) and receptor activator of
NF-kB ligand (RANKL).5,6 With further RANKL stimulation, the
osteoclast precursors become tartrate-resistant acid phospha-
tase (TRAP)-positive mononuclear cells.7 Osteoclasts are
generated by the fusion of mononuclear TRAP cells.8 Activated
mature osteoclasts will develop resorption activity.9 TNF-a is
reported to promote the osteoclastogenesis induced by
RANKL.10
In general, TNF-a induces osteoclast precursor cells to
become osteoclasts in the absence of RANKL. However, these
osteoclasts induced by TNF-a do not have resorbing activi-
ty.11,12 Although some studies have suggested that TNF-a
induces the differentiation of pit-forming osteoclasts, their
findings indicate that osteoclasts induced by TNF-a have
much lower resorption activity than RANKL-induced osteo-
clasts.13 Osteoclast formation and the activity of resorption
are important to the promotion of bone destruction. With
RANKL-pretreatment or with RANKL co-stimulation, osteo-
clast formation induced by TNF-a is accelerated.10 In addition,
it was reported that TNF-a coexisting with RANKL induces
osteoclasts with resorption activity.14 Thus, it is important to
further elucidate the conditions in which osteoclast formation
accelerates and the resorption activities produces in osteo-
clasts by TNF-a stimulation, as this information may have
important therapeutic implications for the control of inflam-
matory bone diseases. However, the details of the effects of
RANKL-pretreatment on the differentiation of pit-forming
osteoclasts induced by TNF-a have not been established.
Osteoclasts can be differentiated from bone marrow
macrophages (BMMs). In generally, 72 h stimulation of RANKL
induces differentiation of mature osteoclast from BMMs.15,16
Many studies reported that only 24 h RANKL treatment had an
effect on the condition of BMMs. Osteoclast-related kinase
increased in BMMs within 24 h after RANKL-stimulation.17
Mizoguchi et al. reported that BMMs were ‘cell cycle-arrested
quiescent osteoclast precursors’ and ‘lineage-committed
osteoclast precursors’ after the cells were stimulated for
24 h with RANKL.16,18 TNF-a stimulation after RANKL pre-
treatment promoted more osteoclast formation from BMMs
compared to before RANKL treatment and simultaneous
RANKL treatment.10,19 Moreover, the acceleration was more
greatly increased by 24 h than by 48 h RANKL pretreatment.20
It was reported that in BMMs pre-cultured with a high
concentration of RANKL, TNF-a alone could induce osteoclast
formation with resorption activity in the absence of RANKL.21
That study showed that RANKL pretreatment to BMMs could
differentiate osteoclasts with resorbing activity by TNF-a
without RANKL. However, the study used only high concen-
trations of RANKL, and the optimal RANKL pretreatment
conditions to produce osteoclasts with resorbing activityinduced by TNF-a are thus not clear. In this study, we
examined the number of osteoclasts and the resorption
activity when BMMs were pretreated with various concentra-
tions of RANKL for 24 h before TNF-a stimulation. We also
evaluated the influence of these concentration of RANKL in
osteoclastogenesis. Our findings help elucidate the mecha-
nisms underlying the osteoclast formation induced by TNF-a,
which may contribute to the treatment of bone diseases.
2. Material and methods
2.1. Animals
Five- to 7-week-old male CB17/Icr+/+ Jcl mice were purchased
from Nihon Clea (Tokyo) and maintained in specific patho-
genic-free conditions at the Biomedical Research Center for
Frontier Life Sciences, Nagasaki University. The animal care
and experiments proceeded according to the Guidelines for
Animal Experimentation of Nagasaki University and with the
approval of the Institutional Animal Care and Use Committee.
2.2. Reagents
Recombinant mouse M-CSF, recombinant mouse soluble
RANKL, recombinant mouse TNF-a, and recombinant mouse
osteoprotegerin (OPG) were purchased from R&D Systems
(Minneapolis, MN, USA). The tartrate-resistant acid phospha-
tase (TRAP) kit for staining of osteoclasts was purchased from
Sigma (St. Louis, MO). The Bone Resorption Assay kit 48 was
purchased from PG Research (Tokyo). The TRACP & ALP Assay
kit for detecting of TRAP activity in the culture was purchased
from Takara Bio (Tokyo).
2.3. Preparation of bone marrow macrophages
Murine bone marrow macrophages (BMMs) were obtained as
described.22,23 Briefly, bone marrow cells were collected from
mouse tibiae and femurs, and red cells were lysed. The cells
were then plated at 1.5  107 to 2  107 cells in 10-cm dishes
with 10 mL of alpha-minimal essential medium (aMEM)
supplemented with 10% fetal bovine serum, 100 U/mL peni-
cillin and 100 mg/mL streptomycin, and cultured in the
presence of 5 ng/mL M-CSF for 12 h. Non-adherent cells were
collected and cultured with 30 ng/mL of M-CSF for 36 h. After
the removal of non-adherent cells, the adherent cells were
collected and used as BMMs. In all subsequent experiments,
BMMs were cultured in the medium containing 30 ng/mL of
M-CSF.
2.4. Osteoclast formation assays
In order to examine the influence of RANKL pretreatment on
osteoclast formation stimulated with TNF-a, after BMMs
(2  104/well) were pretreated at the designated concentration
of RANKL for 24 h, the medium was changed in order to
remove RANKL and the cells were cultured with/without TNF-
a for various periods. In another experiment, 300 ng/mL of
OPG was added with TNF-a. When the cultures were finished,
the cells were stained for TRAP and the number of osteoclasts
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(2.0  104/well) were cultured with 10 ng/mL of RANKL with/
without OPG for 72 h in 96-well plates. To examine various
concentration and period of RANKL stimulation for osteoclast
formation and TRAP activity, BMMs (2.0  104/well) were
cultured with various concentrations of RANKL for the
designated period in 96-well plates. TRAP activity was
measured and the cells were stained for TRAP.
2.5. TRAP staining
Cells were fixed with 4% paraformaldehyde and stained by
using a TRAP kit (Sigma) for the identification of osteoclasts.
TRAP-positive multinucleated cells with three or more nuclei
were considered osteoclasts. The TRAP-positive cells and
osteoclasts were counted under the microscope.
2.6. TRAP activity
TRAP activity was measured according to the protocol of the
TRACP & ALP Assay kit (Takara Bio). Briefly, cells were
solubilized by pipetting with phosphate-buffered saline
(PBS) including 1% NP-40, added substrate solution and
incubated at 37 8C for 60 min for the measurement of TRAP
activity. The reaction was stopped with 0.5 N NaOH, and the
absorbance at 405 nm was measured using a microplate
reader (SH-1000 Lab, Corona, Japan).
2.7. Pit formation assay
BMMs (1  105/well) were seeded into a calcium phosphate
(Ca-P)-coated 48-well plate (PG Research, Tokyo, Japan) used to
measure the resorption activity of osteoclasts. Cells were
cultured with M-CSF alone or with 10 ng/mL of TNF-a, or 10 ng/
mL of RANKL. After the cells were cultured for 120 h, the pit
formation status was examined. To confirm the status of
osteoclast formation, cells in some well were stained for TRAP
after 72 h culture. In another experiment, in order to examine
the effect of RANKL pretreatment on the resorption activities
of osteoclasts induced by TNF-a stimulation, after cells were
stimulated with RANKL at the concentration of 0, 1 or 10 ng/
mL for 24 h, the medium was changed and the cells were
cultured with TNF-a with or without OPG for 96 h. To confirm
the status of osteoclast formation, cells in some well were
stained for TRAP after 48 h of TNF-a addition.
At the end of the culture, cells were removed with 5%
sodium hypochlorite (NaClO), washed with distilled water,
and dried perfectly. Pits were observed by light microscopy,
and photographs were taken with a digital camera (Carl Zeiss
Co., Ltd. Axio Cam HRC). The pit area per well was calculated
from the photographs using Image J software (NIH, Bethesda,
MD).
2.8. Statistics analysis
The statistical analyses were performed using STATMATE III
software (ATMS, Tokyo). Differences among groups were
assessed by a one-factor analysis of variance (ANOVA) and
Tukey’s test. p-Values <0.05 were considered significant.3. Results
3.1. Osteoclast formation induced by TNF-a stimulation
after RANKL pretreatment
After BMMs were stimulated with RANKL at various concen-
trations for 24 h, the medium was changed, TNF-a was added,
and then we examined the time-dependent osteoclast
formation. Almost all of the cells were TRAP-positive at 48 h
after 1 or 10 ng/mL of RANKL pretreatment in the M-CSF-alone
group. A few osteoclasts were observed in this group (Fig. 1A).
However, there were few TRAP-positive cells following 100 pg/
mL RANKL pretreatment (data not shown). In the group
stimulated with 1 ng/mL TNF-a after RANKL pretreatment,
only a few osteoclasts were observed (Fig. 1B). In the 48 h
stimulation with 10 ng/mL TNF-a, on the other hand, the
number of osteoclasts was significantly increased when BMMs
were pretreated with RANKL at 100 pg/mL or more in
comparison with not pretreatment. The increase was particu-
larly higher when the 1 or 10 ng/mL RANKL pretreatment was
used (Fig. 1C).
OPG was added together with TNF-a for the examination of
the influence of RANKL during TNF-a stimulation. In the case
of 10 ng/mL TNF-a stimulation after 10 ng/mL RANKL pre-
treatment, the number of osteoclasts cultured with 300 ng/mL
OPG was not significantly changed compared to without OPG
at 48 h (Fig. 2B). We confirmed that osteoclast formation
stimulated with RANKL was completely inhibited by this
concentration of OPG (Fig. 2A).
3.2. Pit formation assay
The pit formation assay was carried out using a 48-well plate
coated on the bottom with Ca-P to evaluate the activity of
resorption. This plate was coated with a synthetic carbonate
apatite, similar to natural apatite, which can be used as an
alternative to dentine discs. When BMMs were stimulated
with M-CSF alone, there were no TRAP-positive cells or pits.
Many osteoclasts were induced with 72 h RANKL stimulation.
Pits were observed at 120 h after RANKL stimulation. TNF-a
stimulation formed osteoclasts from BMMs, but they did not
make pits (Fig. 3). These results were not inconsistent with
previous reports.11
We next examined the influence of RANKL pretreatment
on the resorption activities of osteoclasts induced by 10 ng/
mL TNF-a. There were no pits after 96 h of TNF-a stimulation
in the 1 ng/mL RANKL pretreatment, although many osteo-
clasts were observed after 48 h of the TNF-a stimulation
(Fig. 4A). Because almost all cells seemed to be apoptotic at
96 h when the cells were stained with TRAP (data not shown),
we considered that pits would be not detected if cells were
cultured for longer periods. In contrast, in the 10 ng/mL
RANKL pretreatment group, many osteoclasts were observed
at 48 h and many pits were detected at 96 h after TNF-a
stimulation (Fig. 4A). In this culture, the pit formation and
area was not significantly changed compare to that without
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Fig. 1 – The number of osteoclasts induced by TNF-a after RANKL treatment. After mouse BMMs were treated with the
designated concentration of RANKL for 24 h, they were cultured with TNF-a. After being stimulated with/without TNF-a for
24, 48 or 72 h in the presence of M-CSF, cells were stained for TRAP and the positive multinuclear cells were counted. M-CSF
alone (A), and TNF-a (1 ng/mL) added (B), and TNF-a (10 ng/mL) added (C) after RANKL treatment. Bars: means W SD.
*p < 0.001 compared to not pretreated with RANKL. Data are representative of three independent experiments.
N.D.: not detectable.








































Fig. 2 – Effect of OPG on osteoclast formation induced by TNF-a after RANKL treatment. BMMs were treated with M-CSF and
RANKL (10 ng/mL) with/without OPG (300 ng/mL) for 72 h (A). After BMMs were treated with 10 ng/mL of RANKL for 24 h,
they were cultured with M-CSF and TNF-a (10 ng/mL) with/without OPG for 48 h (B). The cells were stained for TRAP, and
the number of positive multinuclear cells was counted. Bars: means W SD. Data are representative of three independent
experiments. N.D.: not detectable. N.S.: not significant.
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different of concentration of RANKL
Our present study indicated the importance of 10 ng/mL of
RANKL pretreatment for TNF-a induced differentiation of pit-
forming osteoclasts. Therefore, we checked the effect of thisFig. 3 – Pit formation induced by RANKL or TNF-a. BMMs were cu
mL) in a calcium phosphate (Ca-P)-coated 48-well plate to meas
culture, cells were stained for TRAP. For the examination of pit
microscopy. Arrowheads indicate pit-forming osteoclasts. Reprconcentration of RANKL in osteoclastogenesis. In order to
examine the difference of conditions of osteoclastogenesis we
compared the time- and dose-dependent changes in TRAP
activity and osteoclast formation from BMMs stimulated with
10 ng/mL of RANKL and other concentrations of RANKL. High
TRAP activity was detected following stimulation with 1 andltured with M-CSF alone, RANKL (10 ng/mL) or TNF-a (10 ng/
ure the resorption activity of osteoclasts. After a 72-h
 formation, cells were removed at 120 h and observed by
esentative photographs of TRAP stain and resorption pits.
Fig. 4 – Pit formation induced by TNF-a after RANKL treatment. (A) BMMs were cultured with 10 ng/mL of TNF-a with/
without OPG (300 ng/mL) after cells were treated with M-CSF (30 ng/mL) with/without RANKL (1 or 10 ng/mL) for 24 h in a
Ca-P-coated 48-well plate. Cells were stained for TRAP after TNF-a stimulation for 48 h. In other wells, cells were removed
and pit formation was examined after TNF-a stimulation for 96 h. Representative photographs of TRAP stain and resorption
pits. (B) BMMs were cultured with 10 ng/mL of TNF-a with/without OPG for 96 h after cells were pretreated with 10 ng/mL of
RANKL for 24 h in a Ca-P-coated 48-well plate. After cells were cultured, they were removed and the pit area was measured
with image analyzing software. Arrows indicate resorption pits. Bars: means W SD. Data are representative of three
independent experiments. N.S.: not significant.
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observed following pretreatment with 100 pg/mL of RANKL,
and little activity was observed with 10 pg/mL of RANKL
(Fig. 5A). Many TRAP-positive cells were observed at 72 h and
later when 1 or 10 ng/mL RANKL was used. A few TRAP
positive cells were observed when 100 pg/mL of RANKL was
used, but the positive cells were hardly detected following
10 pg/mL of RANKL (Fig. 5B). These data revealed that the TRAP
activity could be induced in BMMs if the cells were stimulated
with more than 1 ng/mL of RANKL. Many osteoclasts were
differentiated following 10 ng/mL RANKL stimulation for 72 or
96 h, whereas few such cells were observed when 1 ng/mL
RANKL was used (Fig. 5A).4. Discussion
Our findings demonstrated that osteoclast formation by TNF-a
was accelerated in the absence of RANKL when BMMs were
pretreated for 24 h with the concentration of RANKL that could
induce TRAP activity. It was also shown that pit-forming
osteoclasts were differentiated with TNF-a when cells were
pretreated for 24 h with a concentration of RANKL that can
produce pit-forming osteoclasts within 72 h. However, when a
concentration of RANKL pretreatment that is insufficient for the
induction of TRAP activity and osteoclasts was used, neither the
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Fig. 5 – TRAP activity and osteoclast formation with RANKL stimulation. BMMs were cultured with the designated
concentration of RANKL. At 24, 48, 72 and 96 h, TRAP activity was measured using a TRACP and ALP kit (A). The numbers of
TRAP-positive cells (B) and TRAP-positive multinuclear cells (C) were counted following staining for TRAP. Bars:
means W SD. N.D.: not significant. Data are representative of three independent experiments.
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promoted by 10 ng/mL TNF-a after BMMs were stimulated
with 20 ng/mL of RANKL for 3 or 4 d.24 Jules et al. noted that
TNF-a alone could not directly induce BMMs to become
osteoclasts, but when BMMs were stimulated with 100 ng/mL
RANKL overnight, TNF-a stimulation could induce osteoclasts
with resorption activity in the absence of RANKL.21 These
studies showed importance of RANKL pretreatment on
acceleration of osteoclast formation and differentiation of
pi-forming osteoclast induced by TNF-a. However, it is unclear
what the RANKL pretreatment condition was. No studies have
focused on the conditions of RANKL pretreatment, to our
knowledge. In the present investigation, we found thatosteoclast formation by TNF-a can be promoted without co-
existing RANKL -existence when BMMs are pre-stimulated for
24 h with a concentration of RANKL that can induce TRAP
activity within 72 h. With such a concentration of RANKL
pretreatment for 24 h, only a few osteoclasts were formed at
48 h after the medium was changed. In this condition, most of
the other cells were TRAP-positive cells (data not shown).
Hotokezaka et al. showed that TNF-a could promote osteoclast
formation via the fusion of preosteoclasts.25 In the present
study, TNF-a may promote osteoclast formation by accelerat-
ing the fusion of TRAP-positive cells differentiated under the
influence of only RANKL pretreatment. However, the details of
the mechanism underlying the fusion of preosteoclasts are not
a r c h i v e s o f o r a l b i o l o g y 6 0 ( 2 0 1 5 ) 1 2 7 3 – 1 2 8 21280well understood. Further studies are necessary to fully
understand these events.
Our present findings showed that pit-forming osteoclasts
were differentiated by TNF-a without RANKL when cells were
pretreated for 24 h with a concentration of RANKL that
induces osteoclasts, although TNF-a stimulation alone did
not induce resorption activity as occurred in the Kobayashi
et al. study.11 Osteoclasts with resorption activity are
differentiated under stimulation with both RANKL and TNF-
a.21 It was reported that TNF-a stimulation of BMMs can
promote the production of RANKL.26 In the present study there
were no significant differences in the number of pit-forming
osteoclasts formed by TNF-a with or without OPG, which is a
decoy receptor of RANKL. This result shows that co-exist of
RANKL with TNF-a is not necessary for the induction of
resorption activity. In addition, Fuller et al. reported that TNF-
a promoted resorption activity in osteoclasts derived from
rabbits ex vivo and in osteoclasts differentiated from BMMs
stimulated with RANKL in vitro.14 Therefore, the possibility
that TNF-a promoted resorption activity of osteoclasts
differentiated with RANKL pretreatment alone but not newly
differentiated osteoclasts by TNF-a is considered. However,
because in our current findings we observed many more pits
than the number of osteoclasts differentiated with RANKL
pretreatment alone in the present study, we suspect that there
is another mechanism that induces the resorption activity.
Several research groups reported that osteoclasts induced
by TNF-a without RANKL showed resorption activity in the
presence of interleukin (IL)-1.11,12 The signals from RANK (the
receptor of RANKL) or IL-1 receptors were reported to activate
the pathway of tumour necrosis factor receptor-associated
factor 6 (TRAF6).12,27 In TRAF6-deficient mice, osteoclasts were
differentiated but did not have resorption activity, and the
mice developed osteopetrosis.27 Other studies revealed that
the TRAF6 activity is important for the differentiation of pit-
forming osteoclasts stimulated with RANKL.28,29 TNF-a has
been reported to activate TRAF2 and TRAF5 but not TRAF6,30,31
and thus osteoclasts induced by TNF-a may not have resorbing
activity. However, it was reported that pit-forming osteoclasts
can be differentiated from BMMs with highly over-expressed
TRAF2.30 In one study, pit-forming osteoclasts could be formed
with a high concentration of TNF-a (100 ng/mL).14 These
findings show that it is possible to differentiate pit-forming
osteoclasts if the TRAF2 pathway is efficiently activated. But
even if the TRAF2 pathway cannot be sufficiently activated by
TNF-a stimulation alone for the induction of resorbing
activity, we suspect that pit-forming osteoclasts may be
differentiated if RANKL pretreatment that can activate the
TRAF6 pathway exists as in the present study.
Our results confirmed that 24 h RANKL pretreatment
affected osteoclast formation by TNF-a. Using an in vitro
experimental system in which BMMs differentiate into
osteoclasts in the presence of RANKL for 3 d (similar to our
study), Mizoguchi et al. reported that BMMs treated with
RANKL for 24 h became cell cycle-arrested quiescent and
TRAP-negative osteoclast precursor cells.16 They also showed
that the osteoclast formation induced by RANKL was
completely inhibited under the co-existence of hydroxyurea
to block DNA synthesis. However, osteoclasts were differen-
tiated even when hydroxyurea was added after 24 h RANKLstimulation. These studies may indicate that the important
part of differentiation to osteoclasts is induced during the
24 h after RANKL stimulation, even though the above-
mentioned osteoclast precursor cells were TRAP-negative.
In fact, in a study conducted to analyze the mRNA of the gene
expression during osteoclast differentiation, the mRNA
expression of TRAF6 and nuclear factor of activated T-cells,
cytoplasmic 1 (NFATc1) as one of the downstream signalling
molecules of TRF6 increased at 24 h after RANKL stimula-
tion.15 By the blocking of the binding to TRAF6 by selective
TRAF6 decoy peptides at 6 h or 12 h after RANKL stimulation,
osteoclast formation was inhibited.32 These findings suggest
that TRAF6 will be activated within 24 h after RANKL
stimulation and that osteoclast differentiation will be
promoted. Therefore, a sufficient concentration of RANKL
pre-stimulation may be related to the pit-forming osteoclast
formation induced by TNF-a stimulation. Mochizuki et al.
reported that BMMs could not differentiate into dendritic cells
after 24 h RANKL pretreatment, although BMMs are known to
have the capacity to differentiate into not only osteoclasts but
also dendritic cells. These cells were osteoclast committed
cells in which the mRNA expression of NFATc1 as well as
those of cathepsin K, avb3 integrin, RANK, and TRAP were
already increased.33
At each stage in which hematopoietic stem cells differen-
tiate into osteoclasts, the expressions of CD11b as a pan-
surface marker of myeloid lineage cells and F4/80 as a mature
macrophage surface marker are reported to be lower.6,34
Although data is not shown in this study, we analyzed the
expression of CD11b and F4/80 by flow cytometry when BMMs
were stimulated with or without RANKL 10 ng/mL for 24 h in
the presence of M-CSF. As the results, the expression of CD11b
slightly decreased, and the expression of F4/80 significantly
dropped. Analyzing changes of cell surface markers using
comprehensive methods may be helpful for identification of a
RANKL pretreatment condition that induces pit-forming
osteoclasts by TNF-a.
Kostenuik et al. reported that denosumab, a fully human
monoclonal antibody to RANKL for the treatment of bone
diseases, inhibited bone resorption and increased bone
mineral density in patients with osteoporosis or arthritis.35
However, Stolina et al. reported that OPG had no effect on
synovitis.36 It seems reasonable to suppose that the difference
in these results is due to differences in the inhibitory
mechanisms, application timing, processing periods and so
on. Many biologics such as anti-RANKL and anti-TNF-a have
been used in treatments for rheumatoid arthritis, osteoporo-
sis, and giant tumour cells.37–39 These therapies seem to affect
periodontal tissues. It is thus important to further clarify the
mechanisms of the actions of TNF-a and RANKL against
inflammatory bone diseases. Evaluating the effect of RANKL
pre-stimulation for bone resorption accelerated by TNF-a will
be especially useful for the effective inhibitory treatment of
bone resorption when local drug therapy of anti-RANKL
progresses.
In conclusion, the concentration of RANKL pretreatment,
which as well alone can differentiate BMMs into osteoclasts,
may also be important in the generation of pit-forming
osteoclasts by TNF-a. In addition, the effects of TNF-a after
RANKL pretreatment might be independent of RANKL.
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